Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders

• US 9,212,362 B2
• Filed: 12/05/2014
• Issued: 12/15/2015
• Est. Priority Date: 05/21/2010
• Status: Active Grant

• Current Assignee: Universitat Fur Bodenkultur WIEN
• Original Assignee: Universitat Fur Bodenkultur WIEN
• Inventors: Grillari, Johannes, Schraml, Elisabeth, Grillari, Regina, Fortschegger, Klaus
• Primary Examiner(s): Chong, Kimberly
• Application Number:
  US14/561,585
• Publication Number:
  US 20150119450A1
• Time in Patent Office: 375 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/113 targeting other non-coding nucleic acids, e.g. antagomirs
• CPC Class Codes: C12N 2310/141 MicroRNAs, miRNAs
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

Compositions of an inhibitor of a polynucleotide for use in treating or preventing bone disorders such as osteoporosis, osteopenia, bone fracture, bone cancer, as well as impaired bone homeostasis. Preferred compounds to be used in these medical interventions are antagonistic compounds, like nucleic acid molecules, directed against miR-31 and derivatives thereof. Also, methods for diagnosing and compositions for use in diagnosing bone disorders. Compounds to be employed in these diagnostic methods and uses include compounds such as miR-31.

Claims

1. A method for treating a bone disorder or cardiovascular disorder in a subject, comprising the step of administering an effective amount of a microRNA inhibitor composition to a subject, wherein the administration of the microRNA inhibitor composition treats the bone disorder or the cardiovascular disorder, and wherein the composition comprises a polynucleotide having a sequence selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

2, SEQ ID NO;

3, SEQ ID NO;

5, SEQ ID NO;

6, SEQ ID NO;

7, and SEQ ID NO;

8.

2. The method of claim 1, wherein the polynucleotide has the sequence of SEQ ID NO:

1.

3. The method of claim 1, wherein the polynucleotide has the sequence of SEQ ID NO:

2.

4. The method of claim 1, wherein the polynucleotide has the sequence of SEQ ID NO:

5.

5. The method of claim 1, wherein the polynucleotide has the sequence of SEQ ID NO:

6.

6. The method of claim 1, wherein the polynucleotide has the sequence of SEQ ID NO:

7.

7. The method of claim 1, wherein the polynucleotide has the sequence of SEQ ID NO:

8.

8. The method of claim 1, wherein the polynucleotide is selected from the group consisting of an antagomir, a locked nucleic acid (LNA)-containing polynucleotide, and a microRNA sponge.

9. The method of claim 1, wherein the bone disorder is selected from the group consisting of osteoporosis, osteopenia, bone fracture, and impaired bone homeostasis.

10. The method of claim 1, wherein the composition is administered via injection, via inhalation, orally, rectally, vaginally, topically or locally.

11. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

12. The method of claim 1, wherein the polynucleotide is a microRNA sponge.

13. The method of claim 9, wherein the bone disorder is osteoporosis.

14. The method of claim 9, wherein the bone disorder is osteopenia.

15. The method of claim 9, wherein the bone disorder is a bone fracture.